Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 6.0% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) is a biotechnology company specializing in developing CRISPR-based therapies. Recently, NTLA faced a significant downward trend in the stock market.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 6.0% on Feb 5, 2026 19:22

• The decline in NTLA's stock value today might be due to investors selling to realize profits following a previous uptick in price.
• Despite receiving approval for its clinical trial and a raised price target, concerns about the company's long-term profitability may have shifted market sentiment.
• The market may be reacting to the company's ongoing losses despite positive regulatory news, causing uncertainty about its future financial performance.
• Investors might be wary of the continued clinical hold on the MAGNITUDE trial for ATTR-CM, which could be viewed as a risk factor affecting the stock's movement.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Intellia Therapeutics Receives Key Regulatory Clearance for Clinical Trial

Intellia Therapeutics has received crucial regulatory clearance from the U.S. FDA to lift a clinical hold on its MAGNITUDE-2 Phase 3 study for NTLA-2001 (Nex-z), a CRISPR-based therapeutic for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). This follows a previous setback due to a serious adverse event in a related trial. The company has implemented a revised protocol with enhanced patient monitoring and an increased enrollment target, though the original MAGNITUDE trial for ATTR-CM remains on hold.

https://www.ad-hoc-news.de/boerse/news/ueberblick/intellia-therapeutics-receives-key-regulatory-clearance-for-clinical-trial/68554686

Intellia Therapeutics (NTLA) Price Target Increased by 35.10% to 23.94

The average one-year price target for Intellia Therapeutics (NTLA) has been raised by 35.10% to $23.94 per share from $17.72. This new target represents an 83.47% increase from the last closing price of $13.05. Institutional ownership in NTLA has also increased, with total shares owned by institutions rising by 5.02% over the last three months, indicating a bullish outlook.

https://www.nasdaq.com/articles/intellia-therapeutics-ntla-price-target-increased-3510-2394

FDA Clears Intellia Phase 3 ATTRv PN Trial Lifting Key Overhang

The FDA has lifted the clinical hold on Intellia Therapeutics' Phase 3 MAGNITUDE-2 trial for Nexiguran Ziclumeran (Nex-Z), treating hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). This decision allows the crucial gene editing program to proceed after a safety-related pause, removing a significant regulatory concern for investors. Intellia Therapeutics, which is currently loss-making, will continue with the trial under agreed study modifications and enhanced safety monitoring.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/fda-clears-intellia-phase-3-attrv-pn-trial-lifting-key-overh

FDA Clears Intellia Phase 3 ATTRv PN Trial Lifting Key Overhang

The FDA has lifted a clinical hold on Intellia Therapeutics' Phase 3 MAGNITUDE-2 trial of Nexiguran Ziclumeran (Nex-Z) for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), allowing the trial to resume with modified study protocols and enhanced safety monitoring. This decision removes a significant regulatory overhang for Intellia Therapeutics (NasdaqGM:NTLA), enabling a key gene editing program to advance. The company, currently trading at US$13.05, is developing CRISPR-based therapies and, despite being loss-making, shows strong recent momentum.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/fda-clears-intellia-phase-3-attrv-pn-trial-lifting-key-overh/amp

FDA Lifts MAGNITUDE-2 Hold Refocusing Intellia’s ATTR Value Story

The FDA has lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial for hereditary transthyretin amyloidosis with polyneuropathy, allowing the company to resume late-stage development of nexiguran ziclumeran. This decision addresses previous safety concerns and is expected to refocus Intellia's value story, although a separate hold on the cardiomyopathy study remains. The market will now focus on the trial's progression and future regulatory updates, as Intellia's stock has seen recent gains despite longer-term declines.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/fda-lifts-magnitude-2-hold-refocusing-intellias-attr-value-s

Trending Today

Bitcoin ($BTC) Crypto Forecast: Up 8.2% Today

Ethereum ($ETH) Crypto Forecast: Up 13.2% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 11.3% Today

BlackLine, Inc. ($BL) Stock Forecast: Up 5.1% Today

Crowdstrike Holdings Inc. ($CRWD) Stock Forecast: Up 5.0% Today

Chewy Inc ($CHWY) Stock Forecast: Up 5.1% Today

International Paper Company ($IP) Stock Forecast: Up 5.8% Today

Coupang LLC ($CPNG) Stock Forecast: Up 5.1% Today

Oracle Corporation ($ORCL) Stock Forecast: Up 5.1% Today

Aurora Cannabis Inc. ($ACB) Stock Forecast: Up 5.0% Today

Intellia Therapeutics, Inc. Price History

05.01.2026 - NTLA Stock was down 6.0%

• The decline in NTLA's stock value today might be due to investors selling to realize profits following a previous uptick in price.
• Despite receiving approval for its clinical trial and a raised price target, concerns about the company's long-term profitability may have shifted market sentiment.
• The market may be reacting to the company's ongoing losses despite positive regulatory news, causing uncertainty about its future financial performance.
• Investors might be wary of the continued clinical hold on the MAGNITUDE trial for ATTR-CM, which could be viewed as a risk factor affecting the stock's movement.

05.01.2026 - NTLA Stock was down 6.8%

• While the FDA lifted the clinical hold on Intellia's Phase 3 trial for hereditary transthyretin amyloidosis, the stock did not respond positively.
• Despite analysts raising price targets and institutional investors expressing optimism, the stock continued its bearish movement.
• Market reaction may have been influenced by ongoing concerns about a separate clinical hold on the cardiomyopathy study, overshadowing progress in the ATTRv-PN trial.
• Conflicting price targets provided by Baird and H.C. Wainwright possibly introduced uncertainty among investors, contributing to the stock's decline.

04.01.2026 - NTLA Stock was down 5.7%

• The FDA lifting the clinical hold on Intellia's Phase 3 trial for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) was initially seen as a positive development, but the market reacted negatively, causing a 12.6% drop in the stock price.
• Despite the regulatory hurdle being cleared, investors may be concerned about the ongoing hold on the MAGNITUDE cardiomyopathy trial, leading to uncertainty about the company's future pipeline.
• Analysts providing varied ratings and decreased price targets could also contribute to the bearish sentiment, as the market digests the implications of the FDA decision and assesses the company's overall financial health and growth prospects.

20.00.2026 - NTLA Stock was up 5.0%

• Intellia Therapeutics (NTLA) witnessed a significant bullish movement recently, possibly influenced by ARK Invest's continuous buying and increased position in the company.
• Despite conflicting valuations, investor confidence in Intellia's clinical pipeline and overall market trends has supported the stock's upward trajectory.
• The company's recovery from a previous decline, ongoing progress in clinical trials, and favorable analyst recommendations have all reinforced investor confidence and contributed to the positive market movement.
• ARK's consistent investment in Intellia, despite past stock fluctuations, reflects strong confidence in the company's future prospects and the effectiveness of its CRISPR-based therapy approach.

21.00.2026 - NTLA Stock was up 15.0%

• Conflicting valuation signals are evident for the stock, as with a DCF model suggesting undervaluation but a P/S ratio indicating overvaluation compared to industry peers.
• Renewed interest in the stock has been sparked by ARK Investment's increased stake and the upcoming J.P. Morgan Healthcare Conference.
• ARK Invest, led by Cathie Wood, has shown confidence in the company's future prospects by acquiring NTLA shares for three consecutive days.
• Despite positive clinical trial progress and recent gains, the stock's valuation remains a matter of debate among investors and analysts.

27.00.2026 - NTLA Stock was up 5.8%

• NTLA stock soared by 10% today in a strong bullish movement.
• A clinical hold on one of Intellia's advanced gene therapy trials for ATTRv-PN was lifted by the FDA, allowing the company to restart patient enrollment.
• The FDA's approval to resume the trial has instilled confidence in Intellia's gene editing initiatives, leading to a notable surge in the stock price.
• Investors are keenly watching for further regulatory decisions on Intellia's clinical trials, especially concerning the ATTR amyloidosis program, which is expected to impact the stock's performance in the near term.

27.00.2026 - NTLA Stock was up 8.2%

• The rise in NTLA's stock price is linked to increased institutional investment from ARK Invest and positive updates on previous clinical hold concerns.
• CEO John Leonard's statement that a patient fatality in the nex-z program was not due to liver toxicity likely reassured investors and hinted at a potential lifting of the FDA hold, bolstering investor confidence.
• The upcoming regulatory decisions on the company's clinical trials, particularly regarding its hereditary angioedema (HAE) candidate, Lonvoguran Ziclumeran, are key points of interest for investors looking at future growth potential.
• Despite uncertainties around its ATTR amyloidosis program and mixed analyst ratings, ARK Invest's recent buying activity demonstrates investor optimism and readiness to handle the volatility often seen with biotech stocks like NTLA.

22.00.2026 - NTLA Stock was up 5.8%

• NTLA saw a notable bullish trend today, potentially influenced by several key factors:
• A recent surge in the company's stock price and increased attention from ARK Investment and the J.P. Morgan Healthcare Conference have attracted investor interest.
• Varied signals on valuation, including indications of both undervaluation based on a DCF model and potential overvaluation suggested by a high P/S ratio, may have led to market volatility and trading possibilities.
• The generally optimistic outlook for the gene editing industry, underscored by anticipated market expansion and transformative prospects for genetic disease treatment, may have also bolstered NTLA's bullish movement.
• Investors weighing the risks associated with stock volatility, clinical trial results, and regulatory challenges within the gene editing market could have also contributed to NTLA's market performance.

28.00.2026 - NTLA Stock was down 8.8%

• NTLA saw a decline in its stock value as the FDA removed the clinical hold on one of its gene therapy trials for ATTRv-PN, causing uncertainty in the market.
• The ongoing hold on the trial for ATTR-CM due to severe side effects and a patient's death added to the pessimism surrounding NTLA.
• Despite the positive development of the FDA allowing the resumption of patient enrollment in one trial, concerns about regulatory issues and safety continued to impact NTLA's stock performance.
• Investors appear cautious about potential safety implications on NTLA's future trials and its ability to handle regulatory hurdles efficiently.

03.01.2026 - NTLA Stock was down 5.1%

• Despite the FDA lifting the clinical hold on Intellia's MAGNITUDE-2 Phase 3 trial for hereditary transthyretin amyloidosis, the stock plummeted 12.6%, reflecting investor apprehension.
• Diverse analyst ratings and price forecasts for NTLA, along with some analysts lowering their targets despite strong financial performance, likely impacted the downward trend.
• The market's attention towards the trial's advancement, upcoming regulatory developments, and existing clinical, regulatory, and financial uncertainties potentially contributed to the prevailing negative market outlook towards Intellia Therapeutics.

30.00.2026 - NTLA Stock was down 7.6%

• The FDA's decision to lift the clinical hold on Intellia's Phase III trial for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) resulted in a temporary boost in the stock price.
• However, the ongoing hold on the MAGNITUDE trial for cardiomyopathy patients, attributed to severe liver-related side effects, raised uncertainties and potential concerns among investors, contributing to the recent bearish trend.
• Despite the positive development of trial resumptions, persistent safety concerns and regulatory scrutiny surrounding Intellia's gene therapy programs likely influenced investor sentiment, leading to the bearish market activity.
• The diverse analyst ratings and the decrease in the average price target may have also impacted the downward movement, reflecting differing perspectives on the company's future despite its strong financial performance.

30.00.2026 - NTLA Stock was down 6.9%

• The FDA lifted a clinical hold on one of Intellia's late-stage gene therapy trials for hereditary transthyretin amyloidosis, allowing the company to resume patient enrollment. This news initially resulted in a 10% rise in shares.
• Despite the positive development regarding the lifted clinical hold, the bearish movement may be linked to the continued hold on another trial for ATTR-CM due to severe liver-related side effects, including a patient's death.
• Intellia's financial performance remains solid, with revenue growth and strong ratios. However, market sentiment could have been affected by uncertainties related to the paused trial and the necessity for new risk mitigation measures.
• Analysts have provided diverse ratings for Intellia Therapeutics, with some lowering price targets. This may be indicative of concerns about the regulatory obstacles facing the company, despite the promising nature of its gene-editing therapies.